Objective. Angiogenesis is crucial in RA disease progression. Lymphotoxin b receptor (LTbR)-induced activation of the non-canonical nuclear factor-kB (NF-kB) pathway via NF-kB-inducing kinase (NIK) has been implicated in this process. Consequently, inhibition of this pathway may hold therapeutic potential in RA. We describe a novel three-dimensional (3D) model of synovial angiogenesis incorporating endothelial cells (ECs), RA fibroblast-like synoviocytes (RAFLSs) and RA synovial fluid (RASF) to further investigate the contributions of NF-kB in this process.
Introduction
RA is a complex autoimmune disease with several mechanisms contributing to its progression, including pathological angiogenesis [1] . Angiogenesis is the formation of blood vessels from pre-existing vasculature and is a necessary part of physiological processes such as reproduction, development and wound repair [2] . However, angiogenesis can also play a detrimental role in various pathological conditions such as cancer, diabetic retinopathy and chronic inflammatory diseases. In RA, angiogenesis occurs already in the earliest phases of the disease and is considered a switch from acute to chronic inflammation [3] . Consequently, angiogenesis may be an attractive therapeutic target for treating the disease [4] .
The molecular mechanisms underlying pathological angiogenesis are governed by various signalling pathways, including VEGF, Notch and nuclear factor-kB (NFkB) pathways [5] . In vitro models to study this have been developed, but most focus solely on endothelial cells (ECs), while excluding other vital cell types, such as stromal and immune cells. In RA, fibroblast-like synoviocytes (FLSs) produce growth factors, cytokines and MMPs, all of which are essential to pathological angiogenesis [6] .
Other major drivers of angiogenesis, especially in the context of chronic inflammation, are immune cells, which produce pro-inflammatory molecules such as TNFa, IL-1b, IL-6 and IL-8, which can also exert pro-angiogenic effects and fuel neovascularization [79] . Recently, we described that lymphotoxin a 1 b 2 (LTb) and LIGHT (TNFSF14), produced mainly by lymphocytes, stimulate angiogenesis both in the context of RA and in cancer [10] . LTb and LIGHT activate non-canonical NF-kB signalling through lymphotoxin b-receptor (LTbR), which is regulated by NFkB-inducing kinase (NIK) [11] . We reported that NIK is highly expressed in blood vessels in synovial tissues of patients with early arthritis, including RA [12] , and in several tumour tissues [10] . We also demonstrated LTb and LIGHT induce angiogenesis both in vitro and ex vivo in a strictly NIK-dependent manner, suggesting non-canonical NF-kB signalling plays a role in pathological angiogenesis in these diseases [10] . Moreover, we established that NIKpositive vessels in the synovium of early RA patients positively correlated with several disease severity measurements, further implicating the non-canonical NF-kB pathway in RA pathogenesis [12] .
Various attempts have been made to develop coculture systems that include both RA fibroblast-like synoviocytes (RAFLSs) and ECs. However, these systems mainly culture the two cell types in monolayers, layering one on top of the other. Therefore, the readout may rather be a sign of EC proliferation and not necessarily angiogenesis, which includes complex processes such as lumen formation [13, 14] . Recently, a three-dimensional (3D) model of tumour angiogenesis was developed, and it was confirmed that sprouting vessels indeed formed lumen and interacted with surrounding extracellular matrix, hence being representative of true vessel formation [15] . Here, we describe such a 3D model in which RAFLSs and ECs are combined into spheroids embedded in a matrix, which enables formation of capillary-like structures. These capillaries can then be quantified via confocal microscopy and digital image analysis, and compared between experimental conditions. To our knowledge, this is the first description of such a spheroid model using RAFLSs and ECs.
This innovative 3D spheroid model allows us to further study non-canonical NF-kB signalling in angiogenesis associated with RA as well as test methods of inhibiting this pathway to block vessel growth, thus opening an avenue for novel treatments of RA.
Methods

Patient materials
RAFLSs were isolated as previously described [16] and cultured in DMEM (Invitrogen, Carlsbad, CA, USA) with 10% fetal calf serum (FCS), 100 mg/ml penicillinstreptomycin, 2 mM L-glutamine, 10 mM HEPES and 250 mg/ml gentamicin. RA synovial fluid (RASF) was pooled from five biologic naive patients, three of whom were IgM-RF + and three of whom were anti-CCP + . OA synovial fluid (OASF) was pooled from three patients. Patient consent was obtained by all participants in written format according to the Declaration of Helsinki and the study was approved by the medical ethics committee of the Academic Medical Centre, University of Amsterdam, Amsterdam, the Netherlands. Human umbilical vein ECs (HUVECs) were cultured on 1% gelatin in M199 (Invitrogen, Carlsbad, CA, USA) containing 20% FCS, 100 mg/ml penicillinstreptomycin, 50 ng/ml heparin, 25 mg/ml endothelial cell growth supplement (ECGS) and 2 mM L-glutamine.
Spheroid co-culture assay 3D spheroid co-cultures were set up using EC growth medium-2 (EGM-2) (Lonza, Basel, Switzerland), 2% FCS (v/v), hydrocortisone, epithelial growth factor (EGF), insulin-like growth factor-1, ascorbic acid, GA-100, heparin and basic fibroblast growth factor (bFGF)/VEGF. Methocel solution was prepared by dissolving 6 g methylcellulose in 500 ml M199 medium. Cells were incubated in 2 mM solution of CellTracker Green CMFDA or CellTracker Orange CMRA (Molecular probes/Invitrogen, Paisley, UK). Seven hundred and fifty HUVECs and 375 RAFLSs were added to each well of a 96 U-well suspension plate (Greiner BioOne, Stonehouse, UK) in 150 ml of EGM-2 with 20% methocel (v/v). Cells formed spheroids overnight at 37 C. Afterwards, a solution of 1.5 mg/ml of rattail collagen type-I (BD Biosciences, Oxford, UK) was prepared in EGM-2 medium and pH neutralized by 1 M NaOH. The initial layer was deposited in the centre of the wells of four-well chamber slides (iBidi, Martinsried, Germany) as droplets and set at 37 C. Spheroids were resuspended in an equivalent solution of collagen type-I and deposited over the first layer, and incubated at 37 C for 11.5 h. After the collagen gels set, 700 ml of M199 medium containing 2% FCS, 100 mg/ml penicillinstreptomycin, 50 ng/ml heparin, 25 mg/ml ECGS and 2 mM L-glutamine including stimulants or inhibitors were added to www.rheumatology.oxfordjournals.org the wells, and the spheroids formed sprouts for 48 h before fixation with 4% paraformaldehyde (w/v) in Hanks' balanced salt solution (Invitrogen, Carlsbad, CA, USA). Sprouting was imaged with a Leica TCS SP8-X confocal microscope (Leica Camera AG, Wetzlar, Germany), using Â10 magnification. Confocal images corresponding to pre-dyed EC sprouting were quantified using Leica QWin Plus (Leica Camera AG) image analysis software ( Supplementary Fig. S1 , available at Rheumatology Online).
Reagents
Stimuli were purchased from R&D systems (Rochester, MN, USA) and used at the following concentrations: LTb (100 ng/ml), LIGHT (100 ng/ml), VEGF (10 ng/ml) and bFGF(10 ng/ml). Anginex was provided by Prof. Arjan W. Griffioen and used at concentrations of 2.5 and 25 mM. The small molecule NIK inhibitor was resynthesized by AstraZeneca (Gothenburg, Sweden) following the patented procedure [17] . Baminercept (LTbRIg) was generously donated by Biogen Idec (Cambridge, MA, USA) and used at concentrations of 10 and 100 mg/ml ( Supplementary Fig.  S2 , available at Rheumatology Online).
Statistical analysis
All graphs showing spheroid outgrowth quantification represent the averaged parameters with the S.E.M. as error bars. Student's t test was performed to calculate statistical significance, using Prism version 5.0b (GraphPad Software Inc., San Diego, CA, USA). P-values are specified in each experiment. Supplementary Methods for small interfering RNA (siRNA) transfection, immunoblot, NIK kinase assay and ELISA are available at Rheumatology Online.
Results
RASF induces angiogenesis in the 3D model, which can be blocked by anginex
In order to mimic the in vivo situation of synovial angiogenesis, we aimed to develop a technique that allows for the outgrowth of true capillary-like structures in a 3D collagen matrix. To do so, we built upon an approach previously used to study tumour angiogenesis in which cancer cells (MDA-MB-231), normal human dermal fibroblasts and HUVECs were combined to form mini tumour spheroids in which subsequent sprout formation could be quantified [15] . We adapted this strategy in order to study RA angiogenesis and used HUVECs and RAFLSs to provide co-culture interactions for the ECs, mimicking the in vivo situation ( Supplementary Fig. S1 , available at Rheumatology Online). Interestingly, the spheroids grown in basal medium exhibited the capacity to form sprouts even without stimulation (Fig. 1AC ). This was not entirely unexpected, as it has been described that RAFLSs produce several pro-angiogenic factors like VEGF and bFGF, as well as the cytokines TNFa, IL-6 and IL-8. Still, the addition of a mix of established growth factors to the medium (EBM-2 supplement, Lonza) further increased EC sprouting (Fig. 1A and C) , supporting use of the 3D model to study inhibitors of angiogenesis.
The pro-angiogenic capacity of RASF and its effect on neovascularization are well described [79] , and to further simulate the conditions of the inflamed synovium in RA, we added RASF to the spheroids and determined the effects on sprouting. RASF induced a two-fold increase in vessel formation as compared with untreated spheroids (Fig. 1A and B) , further illustrating the importance of RAFLSs as well as SF in promoting pathological synovial angiogenesis associated with RA.
In order to demonstrate that our system acts similarly to other models of angiogenesis, we included an established inhibitor of angiogenesis, anginex, to determine whether sprout formation could be blocked in our 3D model, as previously described in monocellular EC spheroid sprouting and tube formation models [18] . Anginex is an amphipathic b-sheet-forming peptide and works by targeting activated ECs during angiogenesis via galectin-1 while leaving pre-existing vasculature intact [19, 20] . Initial experiments showed that anginex inhibits sprout formation induced by medium containing growth factors (Fig. 1C) , and we could demonstrate that anginex also attenuates RASF-induced sprout formation ( Fig. 1A and C) , which has not been previously described. Together these observations indicate that this novel 3D model, incorporating different cell types and SF, accurately represents synovial angiogenesis and can be used to study the effects of therapeutic interventions on this process.
Activation of non-canonical NF-kB signalling induces angiogenesis in a NIK-dependent manner
We previously demonstrated that the non-canonical NFkB pathway, activated by the LTbR and its ligands LTb and LIGHT, plays a role in pathological angiogenesis associated with RA [10] . To further delineate this process, we investigated the role of the non-canonical pathway in neovascularization in the 3D model. Spheroids stimulated with LTb and LIGHT, as well as with the classical proangiogenic growth factors VEGF and bFGF, featured considerable increases in sprout formation ( Fig. 2A and B ). There were significantly more sprouts induced by LTb and LIGHT as compared with the unstimulated condition, although the levels did not match the sprouting induced by growth factors ( Fig. 2A and 2B ). This indicates that LTb and LIGHT have clear pro-angiogenic effects on ECs and RAFLSs, but they are only partial inducers as compared with the classical promoters of angiogenesis, VEGF and bFGF. Interestingly, OA FLSs showed similar responses when stimulated with activators of the non-canonical pathway, as well as with growth factors or OASF ( Supplementary Fig. S3 , available at Rheumatology Online). In addition, we recently established that LTb and LIGHT also induce proliferation of ECs in a system in which RAFLSs and ECs were cultured together in monolayers and subsequent angiogenic responses by the ECs were visualized through immune-detection of the EC marker CD31 [13, 14] (Supplementary Fig. S4 , available at Rheumatology online). While this method includes the interactions between the two cell types, the quantification of CD31 is primarily a readout of EC proliferation and may not reflect true angiogenesis.
To determine whether the pro-angiogenic effects of LTb and LIGHT in the 3D model were dependent on NIK, the main kinase of the non-canonical pathway, we knocked down gene expression in ECs by siRNA transfection before incorporating the cells into the spheroids ( Supplementary Fig. S5 , available at Rheumatology Online). Sprouting induced by LTb and LIGHT was drastically reduced in the spheroids pre-treated with NIK targeting siRNA as compared with those pre-treated with nontargeting siRNA (Fig. 2C ). Spheroids stimulated with growth factors remained unaffected, which was anticipated, as the non-canonical pathway has not been linked to VEGF or bFGF signalling in ECs. These data demonstrate that LTb-and LIGHT-induced angiogenesis in the 3D model is NIK dependent whereas growth factor-induced sprout formation is not. This is in line with our previous findings in a human microvascular EC tube formation assay [10] .
Baminercept inhibits angiogenesis induced by LTb, LIGHT and RASF Another (upstream) method to target non-canonical NFkB signalling is blocking activation of the LTbR itself.
Baminercept, a soluble LTbRIgG1 fusion protein, acts antagonistically by competing for binding of the activating ligands, LTb and LIGHT [21] . To confirm inhibition of vessel formation by baminercept, we tested whether the fusion protein could block sprouting induced by LTb and LIGHT. Indeed, baminercept strongly reduced vascularization in the 3D spheroid model with a maximal effect at 10 mg/ml and no further reduction in sprout formation observed at higher concentrations (Fig. 3A) . This is likely due to the ability of baminercept to neutralize most or all of the exogenous ligand added to the medium at the 10 mg/ml concentration. Interestingly, when added to cultures stimulated with RASF baminercept reduced sprout formation by > 50% (Fig. 3B) , indicating LTbR ligands and non-canonical NFkB signalling are key drivers of pathological angiogenesis in RA.
Pharmacological NIK inhibitor blocks LTbR-and growth factor-induced sprouting and attenuates angiogenesis caused by RASF Over the last decade, there has been growing interest in developing small molecule inhibitors of NIK [2224] , and to be able to address the role of NIK kinase activity on angiogenesis (as opposed to knocking down the protein and thereby potentially disrupting important proteinprotein interactions) we re-synthesized a recently www.rheumatology.oxfordjournals.org described pharmacological NIK inhibitor [17] and thoroughly characterized the compound. First, its potency to inhibit NIK function was tested, as well as its effects on non-canonical NF-kB signalling in ECs. Using a luciferase kinase assay we determined the IC 50 of the compound to be 10 nM (Fig. 4A) . We then tested the ability of the NIK inhibitor to block non-canonical NF-kB signalling by measuring LTbR-induced changes in p100 protein processing to p52, the downstream effector molecules following NIK activation (Fig. 4B) . Strong reductions in p52 protein levels in ECs were observed at concentrations of 1 mM and higher; however, when the inhibitor was tested in an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to establish its effect on cell viability, the inhibitor proved toxic to both ECs and RAFLSs at levels of 5 mM and higher ( Supplementary Fig. S6A and B, available at Rheumatology Online). Based on this information, we decided to use the inhibitor in the 3D model at concentrations no higher than 2.5 mM.
In the 3D model of synovial angiogenesis, NIK inhibition resulted in sharp reductions in LTbR-induced sprout formation (Fig. 4C) , similar to that observed with the NIKtargeting siRNA (Fig. 2C) . However, in contrast to NIK siRNA, the NIK inhibitor also blocked growth factor-induced sprout formation, which could be due to offtarget effects (e.g. inhibition of tyrosine kinases involved in growth factor signalling and cytoskeleton rearrangement; Supplementary Fig. S6C , available at Rheumatology Online), or alternatively, reflect the importance of the interactions between the RAFLSs and ECs. Thus, to address whether LTbR signalling in RAFLSs may directly contribute to the production of pro-angiogenic factors by these cells, we stimulated RAFLSs with LTb or LIGHT for 24 h, and investigated the effects of conditioned medium on EC proliferation. Interestingly, conditioned media of RAFLSs stimulated with LTb or LIGHT resulted in a significant increase in EC proliferation ( Supplementary Fig. S7 , available at Rheumatology Online). Further analysis revealed that in addition to earlier reported increased production of cytokines and chemokines [2527] , RAFLSs also produce bFGF upon activation of the LTbR ( Supplementary  Fig. S8 , available at Rheumatology Online), which together may be driving the observed proliferative effect on ECs. However, inhibition of non-canonical NF-kB signalling in RAFLSs by NIK siRNA did not abrogate these results, indicating that NIK-independent LTbR-induced signalling events may also contribute to the integrated angiogenic response ( Supplementary Fig. S7 , available at Rheumatology Online), a finding warranting further studies. Nonetheless, these data further identify RAFLSs as active mediators of inflammation-induced angiogenesis rather than just providing stromal support, which underscores the importance of using complex multicellular culture systems vs monocultures to better predict the in vivo effects of inhibitors.
To further evaluate the therapeutic potential of the NIK inhibitor in targeting angiogenesis associated with RA, we determined its effects on vascularization caused by RASF www.rheumatology.oxfordjournals.org and observed that the inhibitor significantly attenuated sprout formation at both concentrations (Fig. 4D) . RASF contains a multitude of factors, including LTb [28] and LIGHT [26] (Supplementary Fig. S9 , available at Rheumatology Online), which can activate several proangiogenic pathways, both in RAFLSs and in ECs. To confirm that this observation was due to NIK inhibition and not to off-target effects, we knocked down NIK expression in both ECs and RAFLSs before incorporation into spheroids. Subsequent analysis revealed that loss of NIK function in both cell types could block RASF-induced sprout formation, in a manner similar to that of the NIK inhibitor, indicating that attenuation of sprout formation was indeed a result of targeting the non-canonical NF-kB pathway ( Supplementary Fig. S10 , available at Rheumatology Online). Based on these findings, the pharmacological NIK inhibitor is capable of blocking factors that cause neovascularization via non-canonical NF-kB signalling in RASF.
Discussion
Angiogenesis is a complex process involving interactions between several cell types to coordinate vessel formation. Therefore, a co-culture model integrating multiple cells better reflects this multifaceted process than a model based solely on ECs. Here, we demonstrate that a 3D co-culture system with ECs and RAFLSs, both central players in neovascularization, can be used as a physiologically relevant representation of angiogenesis associated with RA synovial inflammation. This model is compatible with RASF, which is used as a trigger for vessel formation, further adding to its resemblance of the in vivo process. Importantly, we demonstrate that this method can also be used to test inhibitors of angiogenesis. Because treatments act on two pivotal cell types involved in the angiogenic process, rather than only one, and the model incorporates SF, the 3D model may better predict how novel treatments will behave in more complex in vivo situations, both in preclinical models of arthritis and ultimately in RA patients. Using the 3D model, we identify anginex, a potent inhibitor of angiogenesis in pre-clinical cancer models [19, 29] , as an interesting compound to also study in pre-clinical models of arthritis and determine whether its suppression of angiogenesis can ameliorate the symptoms associated with RA.
Furthermore, our findings continue to support the hypothesis that the non-canonical NF-kB pathway participates in pathological angiogenesis in response to activation of the LTbR [10] . One of the benefits of this model is that each cell type can be manipulated individually before being incorporated into the spheroids, for example, via siRNA-mediated knockdown of genes of interest or potentially overexpression of genes using vectors, thus making it possible to dissect out the molecular mechanisms occurring in the cells that contribute to neovascularization. Using this approach we have demonstrated that the LTbR-induced sprout formation is dependent on NIK expression in ECs. This is of interest because increased NIK expression in ECs has been described in RA synovial tissues, as well as in several tumour tissues [10] . Additionally, the findings that pharmacological NIK inhibition can attenuate vascularization induced not only by LTb and LIGHT but also by growth factors may reflect the importance of cellcell interactions in complex physiologically relevant models of angiogenesis such as our 3D co-culture model. Thus, in addition to providing structural support RAFLSs may also provide crucial signals for vessel formation as suggested by the ability of conditioned medium from LTbR-stimulated RAFLSs to induce EC proliferation. Indeed, RAFLSs have been shown to produce several pro-angiogenic molecules, including VEGF and bFGF, and other factors capable of inducing EC proliferation [3032] . Additionally, our data demonstrate that targeting the non-canonical NF-kB pathway either directly through pharmacological NIK inhibition, or indirectly with a competitive LTbR fusion protein can reduce angiogenesis driven by RASFs. Further in vivo studies testing the pharmacological NIK inhibitor in models of arthritis are required to determine whether targeting the non-canonical pathway can indeed alleviate clinical signs and symptoms. It has already been established that mice lacking NIK are largely protected from arthritis in the antigen-induced arthritis model [33] . This was accompanied by reductions in the total number of synovial blood vessels, as well as by a significant decrease in blood vessels expressing the non-canonical NF-kB-dependent chemokine CXCL12 [10, 34] .
We also demonstrate that the LTbR fusion protein baminercept may exert some of its effects by attenuating angiogenesis induced by LTb and LIGHT. Previously, in vivo studies testing the effects of baminercept in arthritis models proved the molecule to be efficacious in blocking both murine collagen-induced arthritis and adjuvantinduced arthritis [21] . This study focused mainly on the effects of the fusion protein on T cell proliferation, architecture of tertiary lymphoid structures, as well as anticollagen antibody response by B cells. To our knowledge, changes in synovial neovascularization were not investigated, which may prove to be an additional effect of the treatment, since this was observed in an in vivo tumour model of fibrosarcoma [35] . Although baminercept proved to be effective in blocking arthritis in pre-clinical models, in RA clinical trials it failed to meet primary endpoints and ameliorate disease [3638] . Consequently, targeting of the LTbR axis alone may not be enough in the treatment of RA patients. However, blocking associated intracellular signalling pathways such as non-canonical NF-kB signalling, which can also be activated via stimulation of other receptors on ECs such as CD40 [39, 40] and receptor activator of nuclear factor kB (RANK) [41] , using small molecule inhibitors may be more effective.
Mounting evidence implicates immune cells as important contributors to neovascularization both in RA and cancer [4244] . Preliminary experiments indicate the incorporation of immune cells including monocytes/macrophages and lymphocytes, labelled with a third cell tracker dye, in our 3D model is feasible (data not shown), which would further enhance the ability of this model to simulate synovial inflammation. Several studies have also described the benefits of targeting both inflammation and angiogenesis [45, 46] , and such combined treatment options may be valuable as an alternative therapy for patients who do not respond adequately to current immunosuppressive drugs. Therefore, it is important to fully understand the molecular mechanisms underlying pathological angiogenesis in RA for which the novel 3D model may be of use. In addition, this novel model may better predict the in vivo effects of new therapeutic compounds and as such ultimately also reduce the number of animal experiments.
